Childhood Cancer Outcomes Debate
Full Debate: Read Full DebateChris Elmore
Main Page: Chris Elmore (Labour - Bridgend)Department Debates - View all Chris Elmore's debates with the Department of Health and Social Care
(2 years, 4 months ago)
Commons ChamberLeukaemia is the most common cancer in children. For most, the treatment will be chemotherapy and, more recently, the use of targeted therapies such as CAR-T. The treatment will take place over a number of years and there will be many bumps in the road in what is a very difficult journey.
I will never forget the phone call from my wife 15 years ago telling me that our nine-year-old son had leukaemia. For us, it soon became clear that the only route open to us would be a stem cell transplant. We were very fortunate that we found a donor for our son, but far too many children—particularly those from non-white backgrounds—are still not as lucky. There have been great improvements in recent years, but a lot more work still needs to be done.
The transplant process is not easy, involving radiotherapy and isolation to try to avoid infection as the immune system is so weakened, and then there are the post-transplant effects which, in the worst cases, can involve graft versus host disease, which can kill the patient, as well as infertility, premature menopause, fatigue, muscle problems, a higher chance of secondary cancers—I could go on.
We are making medical advancements, and some of the treatment is now far less severe than it was those 15 years ago. But that is the physical side of the illness; what of the psychological issues that children who have had cancer treatment will almost certainly face? About three-and-a-half years ago, I had a debate in this Chamber on this very subject, highlighting what I thought were the problems. Regrettably, those problems are still there today and, with covid, have arguably got worse.
A constituent of mine, Richard Case, lost his son Cian two years ago. Two years ago, I had a debate in this Chamber—the hon. Member for Winchester (Steve Brine) responded for the Government—on international research for children with childhood rare cancers, and looking at how the G7 and the G20 could focus on global research and innovation in tackling childhood cancers. Progress has been limited. Does my right hon. Friend agree that it is time that finding cures for childhood cancers was a global research priority?
I agree, and I think that vital work needs to be carried out now.
Fundamentally, psychological support should not be an add-on. It is not something that we should have to seek or press for our children to receive; it should be part and parcel of the overall treatment programme. For many people, it is about coming to terms not only with the treatment, but with the fear that the illness could come back again. That is a hell of a pressure to be put on a young person.
Young people may also find it difficult to talk to their own families about some of these issues and the concerns they have. That is why professional counsellors and clinical nurse specialists can play an important role in this respect. Reintroduction into school, for example, can be a traumatic experience for young cancer patients, as well as for their classmates, because they might look very different from when they left the school. I remember a young girl telling me that the worst part of what had happened to her was not the treatment, but the fact that she lost her hair—coming to terms with that is very difficult.